drugset / Trial / NCT04209712
Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual Disease
Phase 0
Unknown
6 enrolled
Shanghai iCELL Biotechnology Co., Ltd
Hebei Yanda Ludaopei Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This trial will evaluate the effectiveness and safety of haploid donor-derived in vitro activated natural killer(NK) cells infusion for Treating acute myeloid leukemia Patients With minimal residual disease.
Timeline
- Start
- 2020-01-01
- Primary completion
- 2020-12-31
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TROCULEUCEL | Cell therapy | — | Intravenous |
| Background | aldesleukin | Protein / enzyme biologic | — | Subcutaneous |